Announcements

Announcements
 
 
Paul G. Allen Frontiers Group    [to 2 Feb 2019]
https://www.alleninstitute.org/news-press/
News
New CRISPR-based technique in mice upends rules of genetic inheritance
January 23, 2019
‘Active genetics,’ the parent technique of controversial gene drives, could speed biomedical research, improve mouse models of human disease.
 
 
BMGF – Gates Foundation  [to 2 Feb 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 2 Feb 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 2 Feb 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 2 Feb 2019]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 2 Feb 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center    [to 2 Feb 2019]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 2 Feb 2019]
http://www.ema.europa.eu/ema/
News and press releases
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019
News   01/02/2019
 
 
European Vaccine Initiative  [to 2 Feb 2019]
http://www.euvaccine.eu/news-events
Latest news
Workshop on “In vivo imaging of host response to vaccines and infections”
29 January 2019
Workshop will concentrate on latest advances in non-invasive imaging technologies
 
 
FDA [to 2 Feb 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
January 30, 2019 –
Statement from FDA Commissioner Scott Gottlieb, M.D., on 2019 efforts to advance the development of complex generics to improve patient access to medicines
 
 
Fondation Merieux  [to 2 Feb 2019]
http://www.fondation-merieux.org/
Partner event
4th Meeting of the Global Task Force on Cholera Control (GTFCC) – WASH Working Group
February 12 – 13, 2019 – Les Pensières Center for Global Health, Veyrier du Lac (France)
 
 
Gavi [to 2 Feb 2019]
https://www.gavi.org/
No new digest content identified.
 
 
GHIT Fund   [to 2 Feb 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 2 Feb 2019]
https://www.theglobalfund.org/en/news/
No new digest content identified.
 
 
Hilleman Laboratories   [to 2 Feb 2019]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 2 Feb 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.
 
 
IAVI  [to 2 Feb 2019]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 2 Feb 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 2 Feb 2019]
http://www.ivi.int/
IVI News & Announcements
[Undated]
Prof. Clemens wins Prince Mahidol Award
:: Prof. John D. Clemens, former Director General of IVI, honored with The Prince Mahidol Award in public health
:: Clemens, Prof. Jan R. Holmgren cited for leading the development of oral cholera vaccine
Professor John D. Clemens, former Director General of the International Vaccine Institute (IVI), and Professor Jan R. Holmgren, received the prestigious Prince Mahidol Award in the field of Public Health for their 30 years of work that culminated in the development of an oral cholera vaccine.
Professor Clemens is now the Executive Director of icddr,b in Bangladesh, and Professor Holmgren works at Gothenburg University in Sweden.
Prof. Clemens served as the first Director General of IVI from 1999 to 2011. Under his leadership, IVI coordinated a public-private partnership that led to the development of the world’s first low-cost oral cholera vaccine. The vaccine was transferred to Shantha Biotech in India and EuBiologics in South Korea, which brought the ‘Shanchol’ and ‘Euvichol (Euvichol-Plus)’ vaccines to market. More than 25 million doses of the vaccine have been administered in over 20 countries worldwide. Prof. Holmgren also served on IVI’s Board of Trustees and Scientific Advisory Group in the 2000s, as they continued collaboration to accelerate the development of OCV…
 
 
JEE Alliance  [to 2 Feb 2019]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 2 Feb 2019]
http://www.msf.org/
Selected News; Project Updates, Reports
Burkina Faso
Escalating violence leaves displaced with significant needs
Project Update 31 Jan 2019
 
 
DRC 2018 Ebola outbreaks
Crisis update – January 2019
Crisis Update 30 Jan 2019
 
 
NIH  [to 2 Feb 2019]
http://www.nih.gov/news-events/news-releases
January 30, 2019
NIH-supported scientists develop tool to measure success of HIV cure strategies
— New assay can accurately and easily count the cells in the HIV reservoir.

NIH scientists explore tick salivary glands as tool to study virus transmission and infection
January 29, 2019 — New research focuses on the role of salivary glands in spreading flaviviruses from black-legged ticks to mammals.
 
 
PATH  [to 2 Feb 2019]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 2 Feb 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 2 Feb 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.
 
 
UNICEF  [to 2 Feb 2019]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Statement
Violence, displacement and harsh conditions in Syria kill over 30 children since December
Statement attributable to UNICEF Executive Director Henrietta Fore
31/01/2019
 
Press release
Nearly 3,000 children crossed from Guatemala to Mexico since mid-January – UNICEF
Children on the move should always be protected, stay with their families and be kept out of detention centres, UNICEF says
30/01/2019
 
Press release
Investing in children should be the foundation of Myanmar’s progress and development
‘Children must be top priority’, says UNICEF Executive Director Henrietta Fore at end of three-day visit
30/01/2019
 
Press release
Six months on, Ebola outbreak in eastern Democratic Republic of the Congo now second largest in history
With children accounting for 30% of the confirmed and probable Ebola cases, UNICEF scales up its response to halt spread of the disease
30/01/2019
[See Ebola above for more detail]
  
Press release
UNICEF appeals for $3.9 billion in emergency assistance for 41 million children affected by conflict or disaster
28/01/2019
 
Statement
UNICEF Executive Director Henrietta Fore’s remarks at High-Level Event: “Realizing Myanmar’s Development Vision for Every Child”
28/01/2019
 
Statement
UNICEF Executive Director Henrietta Fore’s remarks at the 2019 U Thant Memorial Lecture
“Building a Peaceful Future by Investing in Children & Young People”
28/01/2019
 
 
Vaccine Confidence Project  [to 2 Feb 2019]
http://www.vaccineconfidence.org/
Posted on 20 Jan, 2019
WHO announces Top Ten Threats to Global Health in 2019
In its 2019 new year message, WHO has named vaccine hesitancy as one of the world’s top 10 global health threats, alongside air pollution and climate change, noncommunicable diseases, global influenza pandemic, fragile and vulnerable settings, antimicrobial resistance,  Ebola and other high-threat
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 2 Feb 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 2 Feb 2019]
https://wellcome.ac.uk/news
Opinion | 29 January 2019
We’ve funded projects with impact and legacy in the latest Public Engagement Fund awards
by Alexandra Parsons
Last November we made another round of awards through our Public Engagement Fund. Alexandra Parsons shares news about future improvements to the fund and tips for writing a strong application.
 
Wellcome Trust | 28 January 2019
Anita Krishnamurthi is Wellcome’s new Head of Education and Learning
 
 
The Wistar Institute   [to 2 Feb 2019]
https://www.wistar.org/news/press-releases
Press Release    Jan. 30, 2019
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute
First-in-class small molecule targeting EBV-driven cancers to enter Phase 1 in 2019
 
 
World Organisation for Animal Health (OIE)   [to 2 Feb 2019]
http://www.oie.int/en/for-the-media/press-releases/2018/
21/01/19
Agriculture Ministers support the OIE in upgrading animal data systems for improved animal disease management
Last Saturday, the 74 Ministers’ delegations participating in the 11th Global Forum for Food and Agriculture (GFFA), to debate digitalisation and smart solutions for future farming, expressed their support to the on-going renovation of the World Animal Health Information System, OIE-WAHIS, acknowledging its key contribution to a more sustainable, responsible and efficient livestock production. They also entrusted the OIE to pursue the implementation of global digital structures promoting an enhanced exchange of information, thereby contributing to strengthen the cross-border fight against animal diseases.
 
 
BIO    [to 2 Feb 2019]
https://www.bio.org/insights/press-release
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 2 Feb 2019]
http://www.dcvmn.org/
No new digest content identified.
 
 
IFPMA   [to 2 Feb 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.
 
 
PhRMA    [to 2 Feb 2019]
http://www.phrma.org/press-room
January 31, 2019     Press Release
Sanofi CEO Olivier Brandicourt Becomes PhRMA Board Chairman
Giovanni Caforio, M.D., Chairman of the Board and CEO, Bristol-Myers Squibb Company and David Ricks, Chairman and CEO, Eli Lilly and Company, assume new posts
Washington, D.C. (January 31, 2019) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) elected three new officers to its board of directors. Olivier Brandicourt, CEO, Sanofi, became chairman of the PhRMA board of directors. Giovanni Caforio, M.D., chairman of the Board and CEO, Bristol-Myers Squibb Company was named chairman-elect and David Ricks, chairman and CEO, Eli Lilly and Company assumed the role of board treasurer…
 
 
Industry Watch    [to 2 Feb 2019]
:: Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents
January 30, 2019 KENILWORTH, N.J.  Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. V114 is also under development for the prevention of IPD in adults. Both indications are currently being studied in Phase 3 clinical trials…
 
:: Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
− Takeda’s dengue vaccine candidate (TAK-003) was efficacious in preventing dengue fever in children and adolescents living in dengue-endemic countries in the ongoing Phase 3 trial –
− The vaccine candidate was found to be well tolerated with no significant safety concerns identified in analyses to date –
− Details will be published in a peer-reviewed journal
CAMBRIDGE, Mass. & OSAKA, Japan– Takeda Pharmaceutical Company Limited [TSE:4502 / NYSE:TAK] (“Takeda”) today announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial showed that the company’s investigational live-attenuated tetravalent dengue vaccine (TAK-003) was efficacious in preventing dengue fever caused by any of the four serotypes of the virus. While review of the extensive data set is ongoing, TAK-003 was well tolerated with no significant safety concerns to date. The TIDES trial is continuing and additional results are expected later this year, along with results from other Phase 3 studies…1